ArticleBreast (Edinburgh, Scotland)2020

Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG).

Tobias Berg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.